LMAT vs. MDXG, CSII, CRY, SIBN, OFIX, GKOS, MMSI, INSP, HAE, and PRCT
Should you be buying LeMaitre Vascular stock or one of its competitors? The main competitors of LeMaitre Vascular include MiMedx Group (MDXG), Cardiovascular Systems (CSII), CryoLife (CRY), SI-BONE (SIBN), Orthofix Medical (OFIX), Glaukos (GKOS), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP), Haemonetics (HAE), and PROCEPT BioRobotics (PRCT). These companies are all part of the "medical" sector.
LeMaitre Vascular (NASDAQ:LMAT) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, community ranking, institutional ownership, dividends, profitability and earnings.
MiMedx Group has higher revenue and earnings than LeMaitre Vascular. MiMedx Group is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.
LeMaitre Vascular has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500.
LeMaitre Vascular currently has a consensus target price of $77.57, suggesting a potential upside of 0.12%. MiMedx Group has a consensus target price of $12.25, suggesting a potential upside of 74.25%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than LeMaitre Vascular.
In the previous week, LeMaitre Vascular had 4 more articles in the media than MiMedx Group. MarketBeat recorded 6 mentions for LeMaitre Vascular and 2 mentions for MiMedx Group. LeMaitre Vascular's average media sentiment score of 1.10 beat MiMedx Group's score of 0.00 indicating that LeMaitre Vascular is being referred to more favorably in the media.
MiMedx Group has a net margin of 18.63% compared to LeMaitre Vascular's net margin of 16.99%. MiMedx Group's return on equity of 39.42% beat LeMaitre Vascular's return on equity.
LeMaitre Vascular received 468 more outperform votes than MiMedx Group when rated by MarketBeat users. However, 77.78% of users gave MiMedx Group an outperform vote while only 70.94% of users gave LeMaitre Vascular an outperform vote.
84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 10.8% of LeMaitre Vascular shares are held by company insiders. Comparatively, 1.3% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
LeMaitre Vascular beats MiMedx Group on 10 of the 19 factors compared between the two stocks.
Get LeMaitre Vascular News Delivered to You Automatically
Sign up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LMAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LeMaitre Vascular Competitors List
Related Companies and Tools
